JP MORGAN/CALL/ELI LILLY & CO/920/0.1/21.06.24 | Delayed Börse Stuttgart 03:44:57 2024-06-20 EDT | ||
| 0.013 EUR | -76.79% |
|
| Current month | -68.89% | ||
| 1 month | -41.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 0.013 | -76.79% |
| 24-06-19 | 0.056 | -49.09% |
| 24-06-18 | 0.11 | -31.25% |
| 24-06-17 | 0.16 | -46.67% |
| 24-06-14 | 0.3 | +36.36% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 03:44 am
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JB4NTX |
| ISIN | DE000JB4NTX4 |
| Date issued | 2023-10-18 |
| Strike | 920 $ |
| Maturity | 2024-06-21 (2 Days) |
| Parity | 10 : 1 |
| Emission price | 0.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.16 € |
|---|---|
| Lowest since issue | 0.013 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Warrants
- Warrant
